72 results about "Amyloid like" patented technology

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

One aspect relates to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on a European population-East Asian data. According to one aspect, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 12 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 80 additional single-nucleotide polymorphisms are used. In addition, the method further includes identifying age, sex, years of education, and APOE genotype as indicators, and thus the ability to predict the risk groups is further enhanced, and the risk groups can be predicted at an early stage with high accuracy.

The invention discloses a preparation method and application of a compound with emulsifying and antibacterial dual functions, and belongs to the technical field of food active packaging materials. The compound is prepared through a two-step method, a synergistic antibacterial mechanism is formed by means of the hydrophobic binding effect of the amyloid fiber and the cationic electrostatic interaction of the chitosan, and meanwhile excellent emulsion stability and antibacterial activity are achieved through the hydrogen bond-electrostatic interaction of the amyloid fiber and the chitosan. When the compound is applied to preparation of the polysaccharide-based composite film, the mechanical property of the film can be remarkably improved. The raw materials are all natural degradable components, the preparation process is simple, and the obtained composite film can efficiently prolong the shelf life of aquatic products, conforms to the green packaging development trend and has important application value in the field of food active packaging.

The invention discloses a method for improving the starch digestibility inhibition effect of a spray drying method by using high amylose, and belongs to the technical field of food processing. According to the invention, highland barley glutelin, low-amylose-content corn starch, normal-amylose-content corn starch and high-amylose-content corn starch are selected, and a spray drying technology is used to simulate an embedding structure of protein in a natural grain structure on the surface of starch particles. The method comprises the following steps: dissolving protein in a 0.02% NaOH solution, then adding corn starch with different amylose contents, stirring for 30 minutes, then carrying out spray drying treatment, controlling the addition amount of the protein to be 10% of the total mass of the starch, setting the inlet temperature of a spray dryer to be 170 DEG C, setting the outlet temperature to be 80 DEG C, and controlling the feeding speed of a peristaltic pump to be 35 mL / min; the appearance of the prepared starch sample is similar to the spatial structure in highland barley grains, and the digestibility of the highland barley grains is reduced.

The invention discloses application of a miR-3960 inhibitor, and belongs to the technical field of biological medicines. The invention aims to find and discover miRNA markers related to AD diagnosis and treatment. Researches on AD pathogenesis discover that expression of the miR-3960 is significantly increased in AD patients, and further cell experiments discover that inhibition of the expression of the miR-3960 significantly improves the influence of A beta1-42 on cell viability, apoptosis, ROS and APP proteins, and the miR-3960 has a significant therapeutic effect on AD. A beta1-42 is a core component of amyloid plaque in the brain of an AD patient, and is widely applied to construction of AD cell models and animal models so as to research pathogenesis and drug evaluation of AD. The miR-3960 inhibitor is used for preparing a medicine for treating the Alzheimer's disease, and the nucleotide sequence of the miR-3960 inhibitor is CCCCCGCCUCCGCCGCCGCC.

Provided herein is a method of detecting an amyloid peptide in a patient sample, including exposing the patient sample to a binding reagent in the presence of an assay binding buffer, thereby immunoprecipitating the amyloid peptide; washing the immunoprecipitated amyloid peptide; eluting the washed, immunoprecipitated amyloid peptide, thereby generating free amyloid peptide; and analyzing the free amyloid peptide with a mass spectrometer.

A peptide-based vaccine for use in the treatment or prevention of amyloid-to-thyroid amyloidosis (ATTR) is provided.

This invention provides material compositions and / or methods suitable for the prevention and / or treatment of protein depletion (protein deficiency), comprising material compositions that preserve the natural function of peptides / proteins while limiting and / or preventing the formation and / or aggregation of said peptides / proteins into amyloid protein. It also provides material compositions and formulations for enhancing peptide / protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, and promoting peptide / protein synthesis and purification.

Provided herein are compositions comprising a nucleic acid encoding an amyloid-beta precursor protein and / or a nucleic acid encoding premature protein-1, cells comprising these compositions, animals comprising these compositions, methods of making these cells and animals, methods of modeling Alzheimer's disease, and methods of preparing such cells and animals. A method of assessing a treatment candidate for treating or ameliorating a symptom or phenotype of Alzheimer's disease, and a method of assessing a treatment candidate for preventing or preventing a symptom or phenotype of Alzheimer's disease.

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

This invention relates to a method for preparing a plasma sample containing amyloid β-peptides for mass spectrometry analysis, comprising the following steps: a) contacting the plasma sample with a denaturing agent; b) performing a first solid-phase extraction step on the solution obtained in step a) to recover a first eluent; c) performing a second solid-phase extraction step on the first eluent obtained in step b) to recover a second eluent; and d) drying the second eluent obtained in step c) and processing it for mass spectrometry analysis, wherein the solution obtained in step d) contains intact amyloid β-peptides Aβ40 and Aβ42.

This invention discloses a nano-flocculator, its preparation method, and its applications. The preparation method includes: preparing a protein amyloid cellulose solution; adding a zirconium salt compound and mixing to obtain a zirconium-loaded protein amyloid cellulose composite solution; and mixing with a polydimethyldiallyl ammonium chloride solution. The nano-flocculator provided by this invention can be stored for a long time at room temperature, is easy to use, and is suitable for improving both sedimentation efficiency and phosphorus removal in municipal and industrial wastewater treatment processes, showing broad engineering application prospects and environmental friendliness.

The invention relates to a method of enriching a sample for amyloid β peptides, comprising (i) contacting the sample with a solid support having thereon an immobilised anti-amyloid β peptide antibody;

The invention pertains to a method for reducing amyloid plaques in the brain of a human suffering from a disease characterized by Aβ plaques in the brain, e.g., Alzheimer's disease. The invention also relates to a method for preventing or reducing amyloid plaques in the brain of a primary prevention subject. Certain aspects of the invention involve methods, doses, or dosing regimens that decrease the risk, frequency, severity, or occurrence of ARIA in subjects.

To provide a new method for forming amyloid fibrils, by which the amyloid fibrils can simply be formed compared with a conventional method.SOLUTION: A method of forming amyloid fibrils from an amyloid fibril forming protein, the method comprising: flowing a fluid comprising the amyloid fibril forming protein into a fluid tube; and conveying the fluid by means for moving the fluid by applying pressure and vacuum to the fluid through the fluid tube by progressively compressing the fluid tube in one direction, thereby forming the amyloid fibrils from the amyloid fibril forming protein.SELECTED DRAWING: Figure 1

The invention discloses application of a theaflavin compound in preparation of a medicine for inhibiting beta amyloid peptide aggregation, and belongs to the technical field of biological medicine. Multi-dimensional experiments prove that the galloyl group in the theaflavin compound can significantly inhibit the formation of Abeta42 amyloid fibers, reduce the generation of toxic oligomers and reconstruct formed oligomers by increasing binding sites with Abeta42 polypeptide and enhancing polar interaction and hydrophobic interaction. The TF3 (containing two galloyl groups) has the optimal anti-Abeta 42 polypeptide aggregation activity, a precise target spot is provided for design of an Abeta amyloid aggregation inhibitor taking the galloyl groups as a core structure, and an experimental basis is provided for application of a natural polyphenol compound in preparation of a medicine for preventing or treating Alzheimer's disease.

The invention discloses application of serum alpha-non-red blood cell ghost protein 1 in preparation of drugs for diagnosing heart light chain amyloidosis diseases, and belongs to the technical field of biological medicines. The serum SPTAN1 protein is used for preparing the medicine for diagnosing the heart light-chain amyloidosis disease, the medicine is limited to be an enzyme linked immunosorbent assay kit, and the kit comprises an antibody of the SPTAN1 protein and further comprises a pre-coated plate, a standard substance, a coating buffer solution, a sample diluent, a confining liquid, horse radish peroxidase, an eluent and a color developing agent. The concentration of the SPTAN1 protein in the serum is measured through an enzyme linked immunosorbent assay kit, and early diagnosis of the heart AL amyloidosis disease is carried out. The invention provides a novel, efficient and sensitive biomarker, namely the serum SPTAN1 protein, early diagnosis of heart AL amyloidosis is realized by detecting the concentration of the SPTAN1 protein in serum, and the serum SPTAN1 protein has an important clinical application prospect.

This invention discloses a composite anticoagulant coating, its preparation method, and its applications, belonging to the field of biomedical technology. This invention provides a novel composite anticoagulant coating. Through the following innovative design: using multi-thiol proteins (bovine serum albumin, lysozyme, etc.) as coating substrates, in-situ bio-orthogonal multiple grafting is performed on their thiol groups and amino groups to achieve multifunctionality of anticoagulation, anti-inflammation, and antibacterial properties; through the amyloid aggregation of proteins, a strong target substrate is formed and anchored, resisting blood flow impact and improving coating stability. This invention, through bio-orthogonal design, modifies the thiol groups and amino groups of the coating proteins separately to achieve non-conflicting multifunctionality. Specifically, by modifying the disulfide bonds (-S-S-) and branched amino groups (-NH2) of the proteins, dual active sites of -SH and -GA are constructed for grafting modification, allowing the grafted substances to achieve their multifunctionality of anticoagulation, anti-inflammation, and antibacterial properties without interference.

The invention discloses a starch flocculation characteristic detection method based on enzymatic liquefaction and visual identification, and relates to the technical field of starch quality detection and performance evaluation.The starch flocculation characteristic detection method comprises the steps that firstly, a sample is prepared, a to-be-detected starch sample and tap water are mixed according to a preset mass-volume ratio, and oscillation and shaking up are conducted to form a starch milk suspension; adjusting the system, namely adjusting the pH value of the starch emulsion suspension to 5.2-6.5 by using a dilute acid or dilute alkali solution; carrying out enzymolysis and liquefaction, adding a proper amount of amylase solution into the starch milk suspension with the adjusted pH value, and continuously oscillating or stirring under a heating condition until the system is completely liquefied; cooling, standing and observing, naturally cooling the completely liquefied liquid to room temperature, standing, observing whether floccules are generated on the liquid level or the solution in the standing process or after standing, and evaluating the aggregation state of the floccules; and finally judging a result. Compared with the prior art, the method has the advantages of rapidness, intuition, low cost, strong simulation, good discrimination and flexibility.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

The invention relates to the technical field of food analysis and detection, in particular to a kit for detecting starch content and a detection method. The kit comprises 4000 to 7000 U / mL of heat-resistant alpha-amylase, 3000 to 6000 U / mL of amyloglucosidase, a GOPOD color developing reagent, a GOPOD color developing reagent buffer solution, a 1.0 mg / mL D-glucose standard solution and a standardized starch sample, and all the reagents are subpackaged in sealed bottles. The kit for detecting the starch content and the detection method have the advantages of simplicity and convenience in operation, rapidness in detection, accurate result, good stability and the like; the application range is wide, and the total starch content in various food, feed, plants and cereal products can be detected.

To provide a method of treating or preventing a disease characterized by deposition of Aβ in a brain, including Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA).SOLUTION: A method of treating or preventing a disease characterized by amyloid beta (Aβ) deposits in the brain of a patient comprises administering to the patient an induction dose of 10 to 60 mg / kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.SELECTED DRAWING: None

The invention is directed to a short-term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by Aβ deposition in the brain, including Alzheimer's disease (AD), Down syndrome, and cerebral amyloid angiopathy (CAA). In some embodiments, patients are administered an induction dose of 10 to 60 mg / kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.

The present application relates to the technical field of Congo red derivative photocatalytic probe application, and particularly relates to a Congo red derivative photocatalytic probe, a preparation method and a use method thereof, comprising a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arene, the arene represents an aromatic heterocycle, and the aromatic heterocycle is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the present application can specifically label amyloid plaques in AD brain tissue slices, the binding affinity is significantly improved (Kd of Aβ 1‑40 The Congo red derivative photocatalytic probe can reveal the molecular heterogeneity of amyloid deposition and the key regulatory role of the mitochondrial autophagy-lysosome axis, provide a new tool for AD pathological mechanism research, support proteomic analysis and pathological mechanism analysis across brain regions (hippocampus / cortex), and protect the molecular structure and application in the research of neurodegenerative diseases.

The invention discloses a probe molecule capable of selectively binding / marking amyloid protein, a preparation method and application of the probe molecule in brain slices of mice suffering from neurodegenerative diseases, and the probe molecule has a structure as shown in a formula I. In the formula I, the value range of n is 0 or 1; r is selected from at least one of p-aminobenzene, p-dimethylaminobenzene, julolidine and 2-dimethylaminonaphthalene. The invention designs a series of photosensitive labeling probes with amyloid variant protein binding capacity. The probe can generate a large amount of active oxygen under the condition of illumination. A marking substrate with nucleophilicity is added into a reaction system, and the probe can realize selective marking of amyloid protein. The probe can realize component analysis of amyloidosis protein in brain slices of mice suffering from Alzheimer's disease and component comparison of amyloidosis protein of mice with different neurodegenerative disease models.

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of:a) contacting said plasma sample with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aβ40 and Aβ42.

The invention discloses a preparation method of kappa-carrageenan-chickpea protein amyloid fiber low-concentration self-assembled composite gel suitable for people with dysphagia, and belongs to the technical field of food processing. The composite gel is formed by taking chickpea protein modified by amyloid fibrosis and kappa-carrageenan as raw materials through a self-assembly effect of the chickpea protein and the kappa-carrageenan under relatively low total solid matter concentration. The gel does not need to introduce an oil phase and a high-energy-consumption homogenization step, the preparation process is simple, and the conditions are mild. The obtained product is soft and smooth in texture, can keep the shape on a fork and can be completely poured from a spoon, the rheological property and swallowing applicability of the product meet the IDDSI 4-level standard through tests, the product is suitable for swallowing disorder crowds with weakened tongue control ability to eat, meanwhile, the resource utilization rate of plant protein and polysaccharide is remarkably increased, and the product cost is reduced.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.